Proximagen Group

Upsher-Smith to acquire U.K.-based Proximagen

Thursday, June 14, 2012 12:33 PM

Upsher-Smith Laboratories, a privately-owned specialty pharmaceutical company of Maple Grove, Minn., has agreed to acquire Proximagen Group, a European biotech focused on the development and commercialization of novel therapeutics for diseases of the central nervous system and inflammation. Upsher-Smith intends to retain operations in Cambridge and London, England.

More... »


Lunudbeck to invest $16 million in Proximagen

Thursday, September 29, 2011 01:00 PM

Danish pharmaceutical group Lundbeck is to invest $6.1 million in British peer Proximagen Group as part of a strategic partnership, the companies said, according to Reuters.

More... »



CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs